Sort   by:  
 Page size 
UnknownIdentification of biomarkers associated with synovitis in rheumatoid arthritis by bioinformatics analyses.
Not available
S-EPMC7502692 | biostudies-literature
UnknownIntegration of Gene Expression Profile Data to Verify Hub Genes of Patients with Stanford A Aortic Dissection.
Not available
S-EPMC6662449 | biostudies-literature
UnknownScreening of gene markers related to the prognosis of metastatic skin cutaneous melanoma based on Logit regression and survival analysis.
Not available
S-EPMC8022370 | biostudies-literature
UnknownFeasibility and Preliminary Efficacy of a Community-Based Addiction Rehabilitation Electronic System in Substance Use Disorder: Pilot Randomized Controlled Trial.
Not available
S-EPMC8087963 | biostudies-literature
UnknownEBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA.
Not available
S-EPMC9235248 | biostudies-literature
UnknownIntegration of Gene Expression Profile Data of Human Epicardial Adipose Tissue from Coronary Artery Disease to Verification of Hub Genes and Pathways.
Not available
S-EPMC6900948 | biostudies-literature
UnknownTG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway.
Not available
S-EPMC9724448 | biostudies-literature
ProteomicsLactylation modification omics analysis of six mouse heart samples was carried out via label-free 4D LC-MS/MS
Post-translational modification (PTM) refers to the chemical modification of proteins following translation, which can regulate protein activity, localization, folding, and interactions with other biomacromolecules (including proteins, nucleic acids, and lipids). Increasing evidence suggests that ma...
ORGANISM(S): Mus Musculus 
PXD076346 |
ProteomicsMolecular Glue Degraders of HuR to Treat BRAF-Mutant Colorectal Cancer
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
PXD077365 |
ProteomicsMolecular Glue Degraders of the RNA Binding Protein HuR to Treat BRAF-Mutant Colorectal Cancer
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2025-12-21 | PXD072281 |
Sort   by:  
 Page size